Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis

• Main Authors: Jia Horng Kao, Shui Yi Tung, Younjae Lee, Satawat Thongsawat, Tawesak Tanwandee, I. Shyan Sheen, Jinzi J. Wu, Hui Li, Barbara J. Brennan, Julian Zhou, Sophie Le Pogam, Isabel Najera, James A. Thommes, George Hill
• 格式: 雜誌
• 出版: 2018
• 主題: Medicine
• 在線閱讀: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85002152541&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/56048

© 2016 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd Background and Aim: Chronic hepatitis C is an important public health problem in Asia. We evaluated the safety, efficacy, and pharmacokinetics of fixed-dose ritonavir-boosted danoprevir plus pegin...